Highlights

  • Solésence reported third-quarter 2026 Revenue of USD 20.2 million, an increase of 38% from a year earlier.
  • Quarterly gross Margin expanded to 39.3%, compared with 23.8% in the corresponding 2025 period.
  • The company recorded USD 3.7 million of net income, its highest quarterly Net Income to date.
  • Solésence shares closed at USD 0.9090 on November 12, easing 0.22% on 1.67 million shares traded.

Solésence Inc. (NASDAQ:SLSN) reported an improvement in both revenue and profitability on November 12, 2026, as the beauty and life-sciences supplier continued expanding its formulation and Manufacturing activities. The company generated USD 20.2 million in third-quarter revenue, up 38% from the corresponding period of 2025. Its shares edged down 0.22% to USD 0.9090 in the November 12 session, with approximately 1.67 million shares changing hands. The contrast between operating gains and modest share-price movement makes the financial detail particularly important.

Ingredients technology supports branded products

Solésence develops scientifically driven materials and finished formulations for customers in beauty and healthcare-related markets. The Business works with Brand partners seeking product performance, innovation and production support. This position differs from selling a single consumer product directly to shoppers: its commercial activity is tied to formulation development, customer launch cycles, manufacturing capacity and repeat purchase volumes. The company has described a framework called Transform and Transcend, intended to combine operational improvements with product innovation and broader market reach.

Revenue and gross margins improve together

Third-quarter revenue increased from USD 14.6 million a year earlier to USD 20.2 million. Gross Profit rose from USD 3.5 million to USD 7.9 million, while gross margin climbed from 23.8% to 39.3%. The improvement signals that the company retained a larger share of sales after direct production costs in the reported quarter. Management connected its operating progress to investments in capacity, efficiency and manufacturing systems. A stronger gross margin can create more room to fund business expenses, but its durability depends on product mix, scale, pricing and manufacturing performance.

Net income reaches a company milestone

Solésence reported USD 3.7 million in net income for the quarter, compared with a USD 1.0 million net loss in the prior-year period. Management described the result as the highest quarterly net income in its history. The figures show an improvement within a defined reporting window and should not be extended mechanically into a full-year Earnings forecast. Demand from brand partners and production scheduling can shift across quarters. The company held a conference call on the reporting date to discuss its financial performance and operating priorities.

Execution turns toward 2027

Management said it had completed the primary implementation and Investment phase of an operational-excellence initiative. The company now aims to use improved capacity and efficiency to meet existing customer requirements while supporting further innovation and international activity. The principal issues to watch include whether revenue growth continues, gross margins remain resilient and new product formulations reach commercial scale. Solésence’s November update provides a substantial operating milestone, but ongoing results will determine whether those gains are repeated in later periods.

Solésence shares closed at USD 0.9090 on November 12, 2026, down 0.22%, with approximately 1.67 million shares traded.